Dx & Vx (A180400) Stock Overview
Engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A180400 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Dx & Vx Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,500.00 |
| 52 Week High | ₩3,850.00 |
| 52 Week Low | ₩1,309.00 |
| Beta | -0.072 |
| 1 Month Change | 95.75% |
| 3 Month Change | 64.32% |
| 1 Year Change | 81.07% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -27.69% |
Recent News & Updates
The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Yet
Dec 18
There's No Escaping Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Muted Revenues Despite A 28% Share Price Rise
Aug 20Recent updates
The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Yet
Dec 18There's No Escaping Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Muted Revenues Despite A 28% Share Price Rise
Aug 20We Think Dx & Vx (KOSDAQ:180400) Has A Fair Chunk Of Debt
Aug 18Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 32% Lower
Feb 14Is Dx & Vx (KOSDAQ:180400) A Risky Investment?
Feb 12Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 28%
Dec 05Positive Sentiment Still Eludes Dx & Vx Co., Ltd. (KOSDAQ:180400) Following 27% Share Price Slump
Oct 21Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% Lower
Jul 15Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%
May 31Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% Hiding
Mar 18Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of Debt
Mar 08Shareholder Returns
| A180400 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 21.7% | 3.6% | 4.3% |
| 1Y | 81.1% | 45.4% | 71.1% |
Return vs Industry: A180400 exceeded the KR Biotechs industry which returned 43.8% over the past year.
Return vs Market: A180400 exceeded the KR Market which returned 70.4% over the past year.
Price Volatility
| A180400 volatility | |
|---|---|
| A180400 Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A180400's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A180400's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 121 | Yong-Gu Lee | www.dxvx.com |
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis drugs; xeropthalmia drugs; anticancer vaccine; and new antibody drugs.
Dx & Vx Co., Ltd. Fundamentals Summary
| A180400 fundamental statistics | |
|---|---|
| Market cap | ₩172.27b |
| Earnings (TTM) | -₩51.81b |
| Revenue (TTM) | ₩29.47b |
Is A180400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A180400 income statement (TTM) | |
|---|---|
| Revenue | ₩29.47b |
| Cost of Revenue | ₩25.33b |
| Gross Profit | ₩4.14b |
| Other Expenses | ₩55.94b |
| Earnings | -₩51.81b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05k |
| Gross Margin | 14.04% |
| Net Profit Margin | -175.80% |
| Debt/Equity Ratio | -1,459.9% |
How did A180400 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 06:52 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dx & Vx Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.